2024 CMR GLOBAL R&D PERFORMANCE METRICS PROGRAMME

Clarivate™

INTRODUCTION

CMR international (CMR), a Clarivate business, is a leader in biopharmaceutical R&D performance analytics. For over 25 years, CMR has worked with the leading global biopharmaceutical companies to assess R&D productivity and provide actionable data and insights, strengthening R&D efficiency and effectiveness. In 2024, CMR will collaborate with biopharmaceutical companies by running the CMR Global R&D programme and its associated modules, which collects metrics on all active substances and associated projects from discovery to launch across all participating companies.

In response to the increasing need for truly innovative and differentiated drug products, ever increasing cost of development, regulatory and payer challenges, the biopharmaceutical industry is seeking new drug development strategies to maximise R&D productivity and therefore, return on investment. The CMR Global R&D programme is a key resource to support R&D decision making and portfolio optimisation within this challenging environment.

USING THE DATA WITH CONFIDENCE

CMR's performance analytics programmes have been the gold standard for collecting and reporting biopharmaceutical R&D performance metrics for over 25 years. Data are collected directly from participating companies, validated and combined into a large blinded reporting database. Containing data on approximately 9,000 active substances, approximately 12,000 new development projects and 2,000 line-extension projects, the Global R&D programme database has the breadth and depth to inform your strategic decision making, support portfolio and project planning and address your R&D key business questions.

METRICS CAPTURED IN THE R&D PROGRAMME

- Cycle times
- Success rates
- Reasons for termination
- Pipeline Volumes
- R&D cost per project
- Proof of concept
- Regulatory strategies
- R&D productivity
- Lifecycle management

PORTFOLIO AND PRODUCTIVITY

The future of any R&D organisation relies on the successful transition of assets through the development pipeline to approval and subsequent launch. Utilising data from the Global R&D programme, decision makers are provided with critical data to answer key business questions such as:

- Does a more focused portfolio deliver more success?
- Which characteristics have the greatest impact upon success?
- What is the direct phase wise cost of development?
- What are the best practices within R&D development and target setting?
- How is your R&D portfolio is performing as compared to your peers?
- Drivers behind your company's performance?

FIGURE 1: BETWEEN PHASE SUCCESS RATES (PHASE II)



FIGURE 2: R&D DEVELOPMENT TIMES





Global R&D programme participants receive a range of online tools (CiMoR), which enable clients to customise metrics to their individual business contexts, supporting portfolio and project management and strategic decision making within today's biopharmaceutical industry. Utilising our online tools, participants can interrogate data to improve their understanding of R&D drivers of key metrics such as cycle times and success rates (Figure 3).

FIGURE 3: ILLUSTRATIVE OF CMR TOOLS (CiMoR) AND REPORTS



2024 GLOBAL R&D PROGRAMME FOCUS

Collecting cost data	Since 2016, CMR has been collecting direct costs for R&D projects for completed Phases; Pre-clinical, I, II, III, Submission and beyond. Recently, discovery costs were added as a pilot data collection. The dataset includes direct cost figures for over 3500 records and CMR plans to grow this dataset and the resulting insights in 2024.
Benchmarking Oncology	Over the last few years CMR has been focusing on the way Oncology data is collected and reported. A significant proportion of oncology is moving towards highly complex and risky program designs such as basket trials and skipping confirmatory phases. As over 40% of the late stage pipeline is made up of oncology drugs, CMR along with a client led steering group has devised an alternative methodology to collect and report on performance of new age Oncology programmes.
Benchmarking Rare diseases and Vaccines	Approximately 15% of the CMR pipeline constitutes of rare diseases. R&D development timelines, attrition rates and productivity for this niche area has been a focus of CMR for over a decade and will continue onwards in 2024. Similarly, CMR has been focused on collecting vaccines data annually as part of the R&D programme since 2012. Over the past decade we have successfully collected performance benchmarking data for hundreds of prophylactic and therapeutic vaccines.

UNDERSTANDING THE DETAILS

If you have any questions relating to this specific or any other CMR programmes, please do contact Jasmin Mehta (jasmin.mehta@clarivate.com) or Beth Deane (beth.deane@clarivate.com). We can demonstrate our on-line CiMoR tools, discuss detailed programme content or focus on your specific business needs and questions.